UNASSIGNED: 4090 Background: Both radicality and minimal invasiveness are essential for the treatment of @entity157 ( @entity157 ), because in 85% of all @entity1 the condition is associated with @entity1575 . @entity505 ion radiotherapy is expected to potentially have both the natures because of its excellent dose distribution and its high cytocidal effect resulting from biologically unique characteristics. METHODS: Forty-four @entity1 with histologically documented @entity157 were treated with 4-fraction @entity505 ion radiotherapy of 52.8 GyE total dose from April 2001 to February 2003. In this report, thirty-six @entity1 with 36 lesions, whose follow-up periods were longer than one year, were the subjects. Fifteen had recurrent @entity5 (locally: 9, regionally: 6). Six were at Stage I of the disease, 20 at Stage II and 10 at Stage IIIA according to the UICC criteria (Sixth Edition). @entity1 -Pugh grade was A in 28 and B in 8 @entity1 . Mean maximum @entity5 size was 4.0 (1.2-7.5) cm in diameter. Anti- @entity5 effect was evaluated by the @entity5 response based on the WHO criteria, cumulative local control rate and overall survival rate calculated by Kaplan-Meier method. NCI-Common @entity137 Criteria (CTC) modified by the @entity96 Working Group and RTOG/EORTC criteria were used for evaluation of @entity137 . RESULTS: During a median follow-up of 23 (15-31) months, no severe adverse effects and no treatment-related @entity204 have occurred. As to the @entity5 response, the ratio of the number of CR and PR to that of all the lesions was 28/36 (78%). Local control rates were 97% and 89% at 1 and 2 year, respectively. Overall survival rates were 92% and 85% at 1 and 2 year, respectively. Within 3 months after the start of therapy, Grade 3 hepatic reaction according to the modified CTC was observed in 3% out of the subjects. Within 3 to 12 months after the start of therapy, no Grade 3 or more hepatic reaction was observed. None of the subjects died of @entity1578 within 1 year after the start of therapy. CONCLUSIONS: Four-fraction @entity505 ion radiotherapy using 52.8 GyE total dose preliminarily proved to be safe and effective for @entity1 with @entity157 associated with @entity409 . No significant financial relationships to disclose.

Four-fraction XXXX ion radiotherapy for @entity157 : results of a phase II clinical trial.

@entity1 :: ('9606', 'Species') :: ['Child', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity96 :: ('MESH:D008113', 'Disease') :: ['Liver Cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'best tumor', 'tumors'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis'] @entity409 :: ('MESH:D008107', 'Disease') :: ['chronic liver disease'] @entity1578 :: ('MESH:D017093', 'Disease') :: ['hepatic failure'] @entity505 :: ('MESH:D002244', 'Chemical') :: ['carbon', 'Carbon'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity505 :: (MESH:D002244,Chemical) :: ['carbon']
